• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

石棉与良性胸膜疾病:一篇叙述性综述。

Asbestos and benign pleural diseases: a narrative review.

作者信息

Ferreiro Lucía, Toubes María E, Rodríguez-Núñez Nuria, Valdés Luis

机构信息

Pulmonology Department, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain.

Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.

出版信息

Breathe (Sheff). 2025 May 13;21(2):240236. doi: 10.1183/20734735.0236-2024. eCollection 2025 Apr.

DOI:10.1183/20734735.0236-2024
PMID:40365090
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12070196/
Abstract

The term "asbestos" is used to refer to a group of silicate minerals that often break down into fibres and whose inhalation over time can cause a number of diseases, especially pleuropulmonary diseases. While the most serious complications are malignant diseases, inhalation of these fibres can also cause benign pleural diseases such as round atelectasis, pleural plaques, diffuse pleural thickening and non-malignant asbestos pleural effusion. Although asbestos is banned in most developed countries (in the European Union, since 2002), it is still used in developing countries. Despite these restrictions, the prevalence of diseases due to inhalation remains high due to the long latency period between the onset of exposure and the onset of disease. In this paper we review benign pleural diseases induced by asbestos exposure, update the diagnostic criteria for these disorders, and describe the approaches suggested so far to differentiate them from malignant pleural diseases.

摘要

术语“石棉”用于指代一类硅酸盐矿物,这类矿物常常会分解成纤维,长期吸入这些纤维会引发多种疾病,尤其是胸膜肺部疾病。虽然最严重的并发症是恶性疾病,但吸入这些纤维也会导致良性胸膜疾病,如圆形肺不张、胸膜斑、弥漫性胸膜增厚和非恶性石棉性胸腔积液。尽管在大多数发达国家(自2002年起在欧盟)石棉已被禁用,但它仍在发展中国家使用。尽管有这些限制,但由于接触石棉到发病之间的潜伏期很长,因吸入石棉而导致的疾病患病率仍然很高。在本文中,我们回顾了石棉暴露引起的良性胸膜疾病,更新了这些疾病的诊断标准,并描述了迄今为止建议的将它们与恶性胸膜疾病区分开来的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9b/12070196/329b0b8fb457/EDU-0236-2024.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9b/12070196/329b0b8fb457/EDU-0236-2024.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9b/12070196/329b0b8fb457/EDU-0236-2024.01.jpg

相似文献

1
Asbestos and benign pleural diseases: a narrative review.石棉与良性胸膜疾病:一篇叙述性综述。
Breathe (Sheff). 2025 May 13;21(2):240236. doi: 10.1183/20734735.0236-2024. eCollection 2025 Apr.
2
Asbestos and the lung in the 21st century: an update.21世纪的石棉与肺:最新进展
Clin Respir J. 2014 Jan;8(1):1-10. doi: 10.1111/crj.12028. Epub 2013 Jul 31.
3
[Asbestos-related pleuropulmonary diseases: pictorial essay].[石棉相关的胸膜肺部疾病:图文综述]
Rev Port Pneumol. 2005 Sep-Oct;11(5):477-85. doi: 10.1016/s0873-2159(15)30519-5.
4
[Pleural and parenchymal lung diseases from asbestos exposure. CT diagnosis].[石棉暴露所致胸膜和肺实质疾病。CT诊断]
Radiol Med. 2000 Nov;100(5):326-31.
5
Clinical Investigation of Benign Asbestos Pleural Effusion.良性石棉性胸腔积液的临床研究
Pulm Med. 2015;2015:416179. doi: 10.1155/2015/416179. Epub 2015 Nov 24.
6
Mesothelioma and asbestos-related pleural diseases.间皮瘤和石棉相关胸膜疾病。
Respiration. 2008;76(1):1-15. doi: 10.1159/000127577. Epub 2008 May 8.
7
[Medical impact of screening of benign pleural lesions associated with the inhalation of asbestos dust].[与吸入石棉粉尘相关的良性胸膜病变筛查的医学影响]
Rev Mal Respir. 1999 Dec;16(6 Pt 2):1286-93.
8
Asbestosis, pleural plaques and diffuse pleural thickening: three distinct benign responses to asbestos exposure.石棉肺、胸膜斑和弥漫性胸膜增厚:对石棉暴露的三种不同良性反应。
Eur Respir J. 1998 May;11(5):1021-7. doi: 10.1183/09031936.98.11051021.
9
Benign asbestos pleural diseases.良性石棉性胸膜疾病
Curr Opin Pulm Med. 2003 Jul;9(4):266-71. doi: 10.1097/00063198-200307000-00004.
10
Asbestos-associated pulmonary disease.石棉相关肺部疾病。
Curr Opin Pulm Med. 2023 Mar 1;29(2):76-82. doi: 10.1097/MCP.0000000000000939. Epub 2023 Jan 11.

本文引用的文献

1
Recognizing the pleura in asbestos-related pleuropulmonary disease: Known and new manifestations of pleural fibrosis.认识石棉相关的胸膜肺疾病中的胸膜:胸膜纤维化的已知和新表现。
Am J Ind Med. 2024 Jan;67(1):73-80. doi: 10.1002/ajim.23553. Epub 2023 Nov 29.
2
Asbestos-associated pulmonary disease.石棉相关肺部疾病。
Curr Opin Pulm Med. 2023 Mar 1;29(2):76-82. doi: 10.1097/MCP.0000000000000939. Epub 2023 Jan 11.
3
Significance of secretory leukocyte peptidase inhibitor in pleural fluid for the diagnosis of benign asbestos pleural effusion.
胸腔液中分泌型白细胞蛋白酶抑制剂对良性石棉性胸腔积液的诊断意义。
Sci Rep. 2021 Jun 21;11(1):12965. doi: 10.1038/s41598-021-92289-7.
4
Retrospective investigation on diagnostic process for benign asbestos pleural effusion (BAPE) using checklist.使用检查表对良性石棉性胸腔积液(BAPE)诊断过程的回顾性调查。
J Occup Health. 2020 Jan;62(1):e12182. doi: 10.1002/1348-9585.12182.
5
A multidisciplinary approach for the diagnosis of benign asbestos pleural effusion: a single-center experience.一种用于诊断良性石棉性胸腔积液的多学科方法:单中心经验。
J Thorac Dis. 2020 Aug;12(8):4338-4346. doi: 10.21037/jtd-20-1119.
6
Pleural Plaques and the Risk of Lung Cancer in Asbestos-exposed Subjects.胸膜斑与石棉暴露人群肺癌风险。
Am J Respir Crit Care Med. 2020 Jan 1;201(1):57-62. doi: 10.1164/rccm.201901-0096OC.
7
Quantification of pleural plaques by computed tomography and correlations with pulmonary function: preliminary study.通过计算机断层扫描对胸膜斑进行定量分析及其与肺功能的相关性:初步研究。
J Thorac Dis. 2018 Apr;10(4):2118-2124. doi: 10.21037/jtd.2018.04.02.
8
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma.英国胸科学会恶性胸膜间皮瘤调查与管理指南。
Thorax. 2018 Mar;73(Suppl 1):i1-i30. doi: 10.1136/thoraxjnl-2017-211321.
9
Recommendations for the Diagnosis and Management of Asbestos-Related Pleural and Pulmonary Disease.石棉相关胸膜和肺部疾病的诊断与管理建议。
Arch Bronconeumol. 2017 Aug;53(8):437-442. doi: 10.1016/j.arbres.2016.12.014. Epub 2017 Mar 6.
10
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.恶性胸膜间皮瘤:调查、诊断与治疗的最新进展
Eur Respir Rev. 2016 Dec;25(142):472-486. doi: 10.1183/16000617.0063-2016.